1. Home
  2. VMD vs HELP Comparison

VMD vs HELP Comparison

Compare VMD & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viemed Healthcare Inc.

VMD

Viemed Healthcare Inc.

HOLD

Current Price

$8.63

Market Cap

313.3M

Sector

N/A

ML Signal

HOLD

HELP

Cybin Inc. Common Stock

N/A

Current Price

$4.63

Market Cap

281.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VMD
HELP
Founded
2006
N/A
Country
United States
Canada
Employees
N/A
50
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
313.3M
281.4M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
VMD
HELP
Price
$8.63
$4.63
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$95.00
AVG Volume (30 Days)
318.8K
1.1M
Earning Date
03-04-2026
07-01-2026
Dividend Yield
N/A
N/A
EPS Growth
32.14
N/A
EPS
0.37
N/A
Revenue
$270,280,000.00
N/A
Revenue This Year
$24.27
N/A
Revenue Next Year
$15.47
N/A
P/E Ratio
$24.96
N/A
Revenue Growth
20.52
N/A
52 Week Low
$5.93
$4.52
52 Week High
$10.06
$8.55

Technical Indicators

Market Signals
Indicator
VMD
HELP
Relative Strength Index (RSI) 46.66 34.75
Support Level $7.93 $4.52
Resistance Level $8.94 $7.28
Average True Range (ATR) 0.51 0.52
MACD -0.06 -0.15
Stochastic Oscillator 39.24 2.23

Price Performance

Historical Comparison
VMD
HELP

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: